Biocon Biologics Recognized as Asia IP Elite for 2024 by IAM, Cementing Leadership in Intellectual Property Excellence

Biocon Biologics Limited, a subsidiary of Biocon Limited (BSE: 532523, NSE: BIOCON), announced today that it has once again been recognized as an Asia IP Elite for 2024 by IAM (Intellectual Asset Management), the world's leading Intellectual Property (IP) publication. This is the eighth consecutive year for Biocon and subsequently its subsidiary Biocon Biologics to make it to this prestigious list.

This prestigious accolade is awarded to a select group of Asia-based organisations that have demonstrated exceptional IP value creation and are considered leaders in the region.

In 2016, Biocon became the first and only Indian pharmaceutical company to be featured on the prestigious ASIA IP ELITE list for its robust IP management and consistent IP value creation.

Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said: "We are humbled to be recognized for the eighth consecutive year as an Asia IP Elite company by IAM, a testament to our commitment to innovation, intellectual property excellence, and patient-centric solutions. This accolade reinforces Biocon Biologics' position as a leading global biosimilars company and underscores the critical role of our robust IP strategy in enabling affordable access to highquality biosimilar therapies worldwide. Our dedicated team continues to place IP at the core of our business, driving value creation and advancing healthcare solutions for millions of patients globally."

Biocon Biologics is leveraging its robust in-house IP strategy and capabilities to enable early entry of biosimilar products to meet patients' needs for affordable therapy in global markets.

Each year, the IAM editorial team conducts an extensive research process, incorporating both quantitative and qualitative analyses, to highlight an exclusive group of leading corporations and research institutions as inductees into the Asia IP Elite. This is a remarkable achievement and well-deserved recognition for the company and its entire IP team.

Each member of the Asia IP Elite showcases excellence in IP value creation and meets the following criteria:

- Placing IP strategy at the centre of its business.

- Obtaining demonstrable, significant and ongoing value from intellectual property as a direct result of the strategies it employs.

- Possessing a senior management that understands the operational and strategic importance of intellectual property.

- Constantly reappraising and improving its IP strategy in order to take advantage of market developments.

This year, 93 entities from India, China, Japan, South Korea, Malaysia, Thailand, Taiwan, Australia, New Zealand, and Singapore featured on the Asia IP Elite 2024 list.

Shares of Biocon Limited was last trading in BSE at Rs. 369.10 as compared to the previous close of Rs. 369.40. The total number of shares traded during the day was 52850 in over 1418 trades.

The stock hit an intraday high of Rs. 374.90 and intraday low of 364.05. The net turnover during the day was Rs. 19510181.00.

Source : Equity Bulls

Keywords

Biocon INE376G01013 BioconBiologics Recognition AsiaIPElitefor2024 IAM